

## **TABLE OF CONTENTS**

Part I. Financial Information

Item 1 — Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Item 2. Management's Discussion and Analysis of Results of Operations and Financial Condition

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Part II. Other Information

SIGNATURES

Exhibit Index

Exhibit 15.1 - Accountants Review

Exhibit 15.2 - Acknowledgement of Ernst & Young

Securities and Exchange Commission  
Washington, D.C. 20549

Form 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended June 30, 2001

Commission file number 000-20699

**DATATRAK International, Inc.**

(Exact name of registrant as specified in its charter)

Ohio

(State or other jurisdiction of  
incorporation or organization)

34-1685364

(I.R.S. Employer  
Identification No.)

20600 Chagrin Boulevard  
Cleveland, Ohio

(Address of principal executive offices)

44122

(Zip Code)

(216) 921-6505

(Registrants telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  
 X  Yes   No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date.

The number of Common Shares, without par value, outstanding as of July 31, 2001 was 3,290,322.

Part I. Financial Information  
Item 1 — Financial Statements

DATATRAK INTERNATIONAL, INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2001	(Note A) December 31, 2000
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 2,155,054	\$ 2,383,244
Short-term investments	6,592,486	9,656,852
Accounts receivable, less allowances	322,867	609,351
Prepaid expenses and other current assets	408,166	377,212
Total current assets	9,478,573	13,026,659
Property and equipment, at cost net of accumulated depreciation and amortization	1,833,990	1,374,352
Other assets	14,767	84,989
Total assets	\$ 11,327,330	\$ 14,486,000
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 153,888	\$ 129,038
Current portion of capital lease obligation	125,152	—
Accrued expenses	708,077	914,114
Deferred revenue	331,323	338,879
Total current liabilities	1,318,440	1,382,031
Capital lease obligation, less current portion	228,160	—
Shareholders' equity:		
Serial preferred shares, without par value, 1,000,000 shares authorized, none issued	—	—
Common shares, without par value, authorized 15,000,000 shares; issued 6,590,322 shares as of December 31, 2000 and June 30, 2001; outstanding 3,290,322 shares as of December 31, 2000 and June 30, 2001	50,364,053	50,356,667
Accumulated deficit	(20,314,691)	(16,987,206)
Treasury shares, 3,300,000 shares at cost	(20,188,308)	(20,188,308)
Foreign currency translation	(80,324)	(77,184)
Total shareholders' equity	9,780,730	13,103,969
Total liabilities and shareholders' equity	\$ 11,327,330	\$ 14,486,000

Note A: The balance sheet at December 31, 2000 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

See notes to condensed consolidated financial statements.

**DATATRAK INTERNATIONAL, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(Unaudited)**

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2001</b>	<b>2000</b>	<b>2001</b>	<b>2000</b>
Revenue	\$ 400,067	\$ 434,580	\$ 1,073,180	\$ 931,922
Direct costs	428,843	366,292	858,461	717,627
Gross profit (loss)	(28,776)	68,288	214,719	214,295
Selling, general and administrative expenses	1,569,019	1,491,277	3,311,653	2,750,743
Depreciation and amortization	241,557	218,450	472,558	405,930
Loss from operations	(1,839,352)	(1,641,439)	(3,569,492)	(2,942,378)
Other income (expense):				
Interest income	99,975	227,190	262,182	465,134
Other income (expense)	2,745	2,424	(20,175)	10,209
Net loss	<u>\$(1,736,632)</u>	<u>\$(1,411,825)</u>	<u>\$(3,327,485)</u>	<u>\$(2,467,035)</u>
Basic and diluted net loss per share	<u>\$ (0.53)</u>	<u>\$ (0.43)</u>	<u>\$ (1.01)</u>	<u>\$ (0.75)</u>
Weighted average common shares outstanding	<u>3,290,322</u>	<u>3,290,322</u>	<u>3,290,322</u>	<u>3,290,322</u>

*See notes to condensed consolidated financial statements.*

**DATATRAK INTERNATIONAL, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(Unaudited)**

	<b>Six Months Ended June 30,</b>	
	<b>2001</b>	<b>2000</b>
<b>Operating Activities</b>		
Net loss	\$ (3,327,485)	\$ (2,467,035)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	472,558	405,930
Other	(207,489)	(274,083)
Changes in operating assets and liabilities:		
Accounts receivable	277,484	(275,446)
Accounts payable and accrued expenses	(181,180)	(313,160)
Other	5,962	(32,916)
Net cash used in operating activities	(2,960,150)	(2,956,710)
<b>Investing activities</b>		
Purchases of property and equipment	(525,810)	(618,638)
Maturities of short-term investments	17,551,000	30,458,000
Purchases of short-term investments	(14,262,760)	(27,454,394)
Net cash provided by investing activities	2,762,430	2,384,968
<b>Financing activities</b>		
Payments under capital lease obligation	(39,788)	—
Repayment (issuance) of notes receivable	25,750	(7,517)
Net cash used in financing activities	(14,038)	(7,517)
Effect of exchange rate on cash	(16,432)	(33,480)
Decrease in cash and cash equivalents	(228,190)	(612,739)
Cash and cash equivalents at beginning of period	2,383,244	2,961,403
<b>Cash and cash equivalents at end of period</b>	<b>\$ 2,155,054</b>	<b>\$ 2,348,664</b>

*See notes to condensed consolidated financial statements.*

**DATATRAK INTERNATIONAL, INC. AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**June 30, 2001**  
**(Unaudited)**

**1. Basis of Presentation**

The accompanying unaudited condensed consolidated financial statements of DATATRAK International, Inc. and subsidiaries (“DATATRAK” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2001 are not necessarily indicative of the results that may be expected for the year ending December 31, 2001. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Form 10-K for the year ended December 31, 2000 (File No. 000-20699).

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that might affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

**2. Net Loss per Share**

The following table sets forth the computation of basic and diluted earnings per share.

	Three Months Ended June 30,		Six Months Ended June 30,	
	2001	2000	2001	2000
Net loss used in the calculation of basic and diluted earnings per share	<u>\$(1,736,631)</u>	<u>\$(1,411,825)</u>	<u>\$(3,327,485)</u>	<u>\$(2,467,035)</u>
Denominator for basic and diluted net loss per share – weighted average Common Shares outstanding	<u>3,290,322</u>	<u>3,290,322</u>	<u>3,290,322</u>	<u>3,290,322</u>
Basic and diluted net loss per share	<u>\$ (0.53)</u>	<u>\$ (0.43)</u>	<u>\$ (1.01)</u>	<u>\$ (0.75)</u>
Common Share options excluded from the computation of diluted net loss per share because they would have an antidilutive effect on net loss per share	<u>1,024,923</u>	<u>893,137</u>	<u>1,024,923</u>	<u>893,137</u>

**DATATRAK INTERNATIONAL, INC. AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**June 30, 2001**  
**(Unaudited)**

**3. Capital Lease Obligation**

During March 2001, the Company entered into an agreement with an unaffiliated third party to lease certain computer equipment. The lease has been recorded as a capital lease. Terms of the lease agreement require the Company to maintain a restricted cash balance equal to the outstanding balance payable on the lease (\$353,312 at June 30, 2001). Future minimum lease payments under the capital lease obligation as of June 30, 2001 are as follows:

<b>Twelve months ending June 30,</b>	
2002	\$145,089
2003	145,089
2004	<u>96,725</u>
	386,903
Less amounts representing interest	<u>33,591</u>
	<u><u>\$353,312</u></u>

**4. Comprehensive loss**

The following table sets forth comprehensive loss.

	<b>Six Months Ended June 30,</b>	
	<b>2001</b>	<b>2000</b>
Net loss	\$(3,327,485)	\$(2,467,035)
Foreign currency translation	<u>(3,140)</u>	<u>(41,647)</u>
Comprehensive loss	<u><u>\$(3,330,625)</u></u>	<u><u>\$(2,508,682)</u></u>

**5. Reclassification**

Certain prior year amounts have been reclassified to conform to the current year presentation.

## **Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition**

The information set forth and discussed below for the three and six month periods ended June 30, 2001 is derived from the Condensed Consolidated Financial Statements included elsewhere herein. The financial information set forth and discussed below is unaudited, but in the opinion of management, reflects all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of such information. The Company’s results of operations for a particular quarter may not be indicative of results expected during the other quarters or for the entire year.

### **General**

DATATRAK is an application service provider (“ASP”) that uses the software known as DATATRAK EDC™ to provide electronic data capture (“EDC”) and other services, which assist companies in the clinical pharmaceutical, biotechnology, contract research organization (“CRO”) and medical device research industries, to accelerate the completion of clinical trials. Approximately 77% of the Company’s assets, or approximately \$8.7 million, are held in cash, cash equivalents and short-term investments. The Company has experienced significant losses and negative cash flow from operations since commencing EDC operations in 1997. The Company is continuing to develop and commercialize the DATATRAK EDC™ software and anticipates that its operating results will fluctuate significantly from period to period. There can be no assurance of the Company’s long-term future prospects.

The Company’s contracts provide a fixed price for each component or service to be delivered. Services provided by DATATRAK that are in addition to those provided for in its contracts are billed on a fee for service basis for services completed. Generally, these contracts range in duration from several months to several years. The ultimate contract value is dependent upon the length of the customer’s use of DATATRAK EDC™ and the services provided by DATATRAK. As services are performed over the life of the contract, revenue is recognized under the percentage of completion method utilizing units of delivery. Costs associated with contract revenues are recognized as incurred. These contracts can be terminated by the customer with or without cause. DATATRAK is entitled to payment for all work performed through the date of notice of termination and for recovery of some or all costs incurred to terminate a contract. The termination of a contract will not result in a material adjustment to revenue or costs previously recognized.

DATATRAK is also a seller and licensor of software. Generally, revenue is recognized upon delivery of sold software. Licensing revenue is recognized ratably over the life of the license. To date, DATATRAK has not recognized any revenue from software sales.

At June 30, 2001, DATATRAK’s backlog was \$5.5 million. Due to DATATRAK’s early stage of development and its low level of backlog, there can be no assurance as to its future levels of revenue. The Company is continuing its efforts to attract new business, however, there can be no assurance as to the results of the Company’s efforts to attract new business, nor as to the timing of revenues associated with new or existing backlog.

### **Results of Operations**

#### *Three months ended June 30, 2001 compared with three months ended June 30, 2000*

Revenue for the three months ended June 30, 2001 decreased 7.0% to \$400,000, as compared to \$430,000 for the three months ended June 30, 2000. The lack of growth was due to the slower than expected development and conversion of backlog into revenue during 2001. The Company has recently increased its sales and marketing staff in order to attract more new business and grow backlog.



Direct costs of revenue, mainly personnel costs, were \$430,000 and \$370,000 during the three months ended June 30, 2001 and 2000, respectively. The 16.2% increase in direct costs was the result of increased personnel costs of \$140,000 caused by the addition of employees, in anticipation of increases in backlog and revenue, to assure the quality delivery of the Company's services. These additional personnel costs were offset by a \$70,000 decrease in other direct costs, mainly travel expenses and other costs, which are passed through to the Company's customers.

Selling general and administrative expenses ("SG&A") include all administrative personnel costs, business and software development costs, and all other expenses not directly chargeable to a specific contract. SG&A expenses increased by 6.7 % to \$1.6 million from \$1.5 million for the three months ended June 30, 2001 and 2000, respectively. During the three months ended June 30, 2001, there was a \$220,000 increase in personnel costs caused by an increase in sales and marketing and software development personnel. This increase was offset by the absence of a one-time, non-cash charge of \$110,000 recorded during the three months ended June 30, 2000, related to compensation expense on stock options, approved by the Company's shareholders, which have exercise prices below market value on the approval date.

Depreciation and amortization expense increased to \$240,000 during the three months ended June 30, 2001 from \$220,000 during the three months ended June 30, 2000. The increase was the result of depreciating capital expenditures associated with the building of DATATRAK's information technology infrastructure.

Other income decreased to \$100,000 during the three months ended June 30, 2001 from \$230,000 during the three months ended June 30, 2000. Other income includes interest income which decreased \$130,000 for the three months ended June 30, 2001, compared to June 30, 2000, due to the Company's use of cash to fund its operating losses and other working capital needs and decreasing interest rates on the Company's short-term investments.

*Six months ended June 30, 2001 compared with six months ended June 30, 2000*

Revenue for the six months ended June 30, 2001 increased 18.3% to \$1.1 million, as compared to \$930,000 for the six months ended June 30, 2000. The low level of growth was due to the slower than expected development and conversion of backlog into revenue during 2001. The Company has recently increased its sales and marketing staff in order to attract more new business and grow backlog.

Direct costs of revenue, mainly personnel costs, were \$860,000 and \$720,000 during the six months ended June 30, 2001 and 2000, respectively. The 19.4% increase in direct costs was mainly the result of increased personnel costs of \$180,000 caused by the addition of employees, in anticipation of increases in backlog and revenue, to assure the quality delivery of the Company's services. These additional personnel costs were offset by a \$40,000 decrease in other direct costs, mainly travel expenses and other costs, which are passed through to the Company's customers.

SG&A expenses increased by 17.9% to \$3.3 million from \$2.8 million for the six months ended June 30, 2001 and 2000, respectively. During the six months ended June 30, 2001, there was a \$620,000 increase in personnel costs caused by an increase in sales and marketing and software development personnel. This increase was offset by the absence of a one-time, non-cash charge of \$110,000 recorded during the six months ended June 30, 2000, related to compensation expense on stock options, approved by the Company's shareholders, which have exercise prices below market value on the approval date.

Depreciation and amortization expense increased to \$470,000 during the six months ended June 30, 2001 from \$410,000 during the six months ended June 30, 2000. The increase was the result of depreciating capital expenditures associated with the building of DATATRAK's information technology infrastructure.

Other income decreased to \$240,000 during the six months ended June 30, 2001 from \$480,000 during the six months ended June 30, 2000. Other income includes interest income which decreased \$200,000 for the six months ended June 30, 2001 compared to June 30, 2000, due to the Company's use of cash to fund its operating losses and other working capital needs and decreasing interest rates on the Company's short-term investments.

## **Liquidity and Capital Resources**

Since its inception, the Company's principal sources of cash have been cash flow from operations and proceeds from the sale of equity securities. During 1999, the Company also generated \$15.6 million in cash through the sale of its Clinical Business and \$1.3 million in cash from a favorable legal settlement. The Company's investing activities primarily reflect capital expenditures and net purchases of short-term investments.

The Company's contracts usually require a portion of the contract amount to be paid at the time the contract is initiated. Additional payments are generally received upon completion of negotiated performance milestones throughout the life of the contract. All amounts received are recorded as a liability (deferred revenue) until work has been completed and revenue is recognized. Cash receipts do not necessarily correspond to costs incurred or revenue recognized. The Company typically receives a low volume of large-dollar receipts. Accounts receivable will fluctuate due to the timing and size of cash receipts. Accounts receivable (net of allowance for doubtful accounts) was \$320,000 at June 30, 2001 and \$610,000 at December 31, 2000. Deferred revenue was \$330,000 at June 30, 2001 and \$340,000 at December 31, 2000.

Cash and cash equivalents decreased \$230,000 during the six months ended June 30, 2001. This was the result of \$2.8 million provided by investing activities, offset by \$3.0 million used in operating and financing activities. Investing activities included net proceeds of \$3.3 million from purchases and maturities of short-term investments offset by \$530,000 used to purchase property and equipment. A capital lease obligation of \$390,000 is excluded from financing and investing activities on the Condensed Consolidated Statement of Cash Flows, entered into during the six months ended June 30, 2001. Cash used for operating activities resulted from the funding of net operating losses and other working capital needs.

At June 30, 2001, the Company had working capital of \$8.2 million, and its cash, cash equivalents and short-term investments totaled \$8.7 million. The Company's working capital decreased by \$3.5 million since December 31, 2000. The decrease was primarily the result of the \$3.3 million decrease in cash, cash equivalents and short-term investments for funding operations.

The Company is responsible for funding the future development and testing of the DATATRAK EDC™ software. The Company will continue to invest in the development of the DATATRAK® process. The Company's operations and the EDC market are still in a developmental stage. DATATRAK has experienced marginal revenue growth, however, the Company anticipates negative cash flow from operations during 2001, as it continues to build its operational and business development infrastructure. The Company anticipates capital and related expenditures of approximately \$1.0 million over the next nine to twelve months for continued commercialization and product development of DATATRAK EDC™, which the Company expects to fund from existing cash and cash equivalents, maturities of short-term investments and cash flow from operations. The Company believes that its cash and cash equivalents, maturities of short-term investments and cash flow from operations, together with its existing sources of equity, may not be sufficient to meet its working capital and capital expenditure requirements for the next year, and anticipates that it will need to raise additional funds for working capital by selling debt or equity securities or through other arrangements. Additional capital may not be available on acceptable terms, if at all.

## **Inflation**

To date, the Company believes the effects of inflation have not had a material adverse effect on its results of operations or financial condition.

## **Interest Rate Risk**

The Company has fixed income investments consisting of cash equivalents and short-term investments, which may be affected by changes in market interest rates. The Company does not use derivative financial instruments in its investment portfolio. The Company places its cash equivalents and short-term investments with high-quality financial institutions, limits the amount of credit exposure to any one institution and has established investment guidelines relative to diversification and maturities designed to maintain safety and liquidity. Investments are reported at amortized cost, which approximates fair value.

## **Foreign Currency Risk**

The Company's foreign sales and results of operations are subject to the impact of foreign currency fluctuations. Approximately 17% of the Company's revenue for the six months ended June 30, 2001 was earned in Germany. The Company manages its risk to foreign currency exchange rates by maintaining foreign currency bank accounts in currencies which it regularly transacts business. The Company does not currently hedge against the risk of exchange rate fluctuations.

## **Information About Forward-Looking Statements**

Certain statements made in this Form 10-Q, other SEC filings or written materials or orally by the Company or its representatives may constitute forward-looking statements that are based on management's current beliefs, estimates and assumptions concerning the operations, future results and prospects of the Company and the clinical pharmaceutical research industry in general. All statements that address operating performance, events or developments that management anticipates will occur in the future, including statements related to future revenue, profits, expenses, income and earnings per share or statements expressing general optimism about future results, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 ("Exchange Act"). In addition, words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," variations of such words, and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the safe harbors created in the Exchange Act. Factors that may cause actual results to differ materially from those in the forward-looking statements include the ability of the Company to absorb corporate overhead and other fixed costs in order to successfully market the DATATRAK EDC™ software; the development and fluctuations in the market for electronic data capture technology; the degree of the Company's success in obtaining new contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; dependence on key personnel; governmental regulation; the early stage of the Company's ASP operations; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not exclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry.

## **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

The Company is exposed to market risk from changes in interest rates and foreign currency exchange rates since it funds its operations through long-and short-term investments and has business transactions in German Deutschmarks.

**Part II. Other Information**

Item 1. Legal Proceedings

None.

Item 2. Changes in Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

At the Annual Meeting of Shareholders held on June 1, 2001, the Company’s shareholders voted to elect Jeffrey A. Green, Timothy G. Biro, Robert M. Stote and Jerome H. Kaiser each to an additional two-year term as a director of the Company.

The following is a summary of the voting:

Votes	Jeffrey A. Green	Timothy G. Biro	Robert M. Stote	Jerome H. Kaiser
For	2,447,165	2,754,455	3,045,201	3,045,201
Withheld	603,191	295,901	5,155	5,155

Item 5. Other Information

None.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

See the Exhibit Index at page E — 1 of this Form 10 — Q.

(b) Reports on Form 8-K

No reports were filed on form 8-K during the three months ended June 30, 2001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		DATA TRAK International, Inc.
		Registrant
Date:	8/13/01	/s/ Jeffrey A. Green
		Jeffrey A. Green, President and Chief Executive Officer and a Director (Principal Executive Officer)
Date:	8/13/01	/s/ Terry C. Black
		Terry C. Black, Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary (Principal Financial Officer)

**Exhibit Index**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>	<b><u>Page</u></b>
4.1	Specimen Certificate of the Company’s Common Shares, without par value	(B)
4.2	Second Amended and Restated Registration Agreement, dated July 15,1994, as amended on June 1, 1995 and February 5, 1996	(A)
10.1	Amended and Restated 1994 Directors’ Share Option Plan*	(C)
10.2	Amended and Restated 1996 Outside Directors’ Stock Option Plan*	(C)
10.3	Amendment No. 2 to the Amended and Restated 1996 Outside Directors’ Stock Option Plan*	(F)
10.4	Amended and Restated 1992 Share Incentive Plan*	(C)
10.5	Amended and Restated 1996 Key Employees’ and Consultants Stock Option Plan*	(C)
10.6	Amendment No. 2 to the Amended and Restated 1996 Key Employees’ and Consultants Stock Option Plan*	(G)
10.7	Form of Indemnification Agreement*	(A)
10.8	Employment Agreement between the Company and Jeffrey A. Green, dated February 5, 2001*	(H)
10.9	Employment Agreement between the Company and Terry C. Black, dated February 5, 2001*	(H)
10.10	Separation Agreement between the Company and Terry C. Black, dated December 22, 1998*	(E)
10.11	Employment Agreement between the Company and Marc J. Shlaes dated July 2, 1998*	(B)
10.12	Employment Agreement between the Company and Wolfgang Summa, dated December 29, 2000*	(H)
10.13	DATATRAK International, Inc. Retirement Savings Plan*	(D)
10.14	1999 Outside Director Stock Option Plan*	(G)
15.1	Independent Accountants’ Review Report	
15.2	Acknowledgement of Ernst & Young LLP	

\* Management compensatory plan or arrangement.

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>	<u>Page</u>
(A)	Incorporated herein by reference to the appropriate exhibit to the Company’s Registration Statement on Form S-1 (Registration statement No. 333-2140).	
(B)	Incorporated herein by reference to the appropriate exhibit to the Company’s Form 10-K for the year ended December 31, 1999 (Commission file No. 000-20699).	
(C)	Incorporated herein by reference to the appropriate exhibit to the Company’s Registration Statement on Form S-8 (Registration statement No. 333-16061).	
(D)	Incorporated herein by reference to the appropriate exhibit to the Company’s Registration Statement on Form S-8 (Registration statement No. 333-26251).	
(E)	Incorporated herein by reference to the appropriate exhibit to the Company’s Form 10-K for the year ended December 31, 1998 (Commission file No. 000-20699).	
(F)	Incorporated herein by reference to the appropriate exhibit to the Company’s Schedule 14A dated March 17, 1999 (Commission File No. 000-20699).	
(G)	Incorporated herein by reference to the appropriate exhibit to the Company’s Schedule 14A dated May 3, 2000 (Commission File No. 000-20699).	
(H)	Incorporated herein by reference to the appropriate exhibit to the Company’s Form 10-K for the year ended December 31, 2000 (Commission file No. 000-20699).	